Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Alps Pharmaceutical Industrial Co., Ltd.
483
•Alps Pharmaceutical Industrial Co., Ltd.•October 13, 2025

Alps Pharmaceutical Industrial Co., Ltd. – FDA 483, Oct 13, 2025

Record Details

During an FDA inspection conducted from October 13-17, 2025, Alps Pharmaceutical Ind. Co., Ltd., an Active Pharmaceutical Ingredients (API) manufacturer located in Hida City, Japan, received a Form FDA 483 outlining two significant observations. These observations signal potential deviations from Good Manufacturing Practices and require the company to implement corrective actions.The first observation pertained to the Quality Control (QC) laboratory"s failure to follow its established written procedure for synchronizing laboratory instrument times. Specifically, the hardware display times of High-Performance Liquid Chromatography (HPLC) instruments, used for release testing of U.S.-bound APIs, were not synchronized with the network LabSolution software, exceeding the specified tolerance.The second observation highlighted deficiencies in the microbiological laboratory. There was no established written procedure for cleaning incubators, leading to the discovery of mold and mildew in an incubator used for testing U.S.-bound APIs. Furthermore, the laboratory lacked an established written procedure for properly labeling prepared media plates, with current practices omitting crucial details such as analyst initials, inoculation dates, and traceable sample identification.Alps Pharmaceutical is expected to address these issues by implementing robust corrective and preventive actions to ensure the integrity of their data, the cleanliness of their testing environments, and the overall quality and safety of APIs distributed to the United States.

Company
Alps Pharmaceutical Industrial Co., Ltd.
Inspection date
October 13, 2025
Product type
drugs
Office
Office of Inspections and Investigations
People
  • Kham Phommachanh (Investigator)
  • Takeshi Okada (President)
View Company Profile

ID · b776ea72-c92e-492a-8d92-cae0527eea3c

Violation Codes2
FD&C Act 704(b)21 U.S.C. 374(b)

Full citation text and observation details available on the Dashboard.

Other documents for Alps Pharmaceutical Industrial Co., Ltd.
  • 483 - 2023-05-26May 26, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Alps Pharmaceutical Industrial Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.